Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD

Summary

The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Peripheral Arterial Occlusive Disease-related clinically relevant ulcers) and safety (by monitoring adverse events) of one dose of allo-APZ2-PAOD administered intramuscularly into an affected lower leg of patients with Peripheral Arterial Occlusive Disease.

Timeline

Start

2018-03-05

Primary completion

2020-05-15

Completion

2020-05-15

Outcome

Outcome not reported

Stopped (Enrollment): “Very slow recruitment of patients and the current COVID-19 pandemic situation.”

Drugs

Indications